Edurant (Rilpivirine, TMC278): News & Research
- Rilpivirine Shows Potent Activity (Summer/Fall 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- TMC278 (Rilpivirine) Stands Up to Efavirenz in Battle of First-Line NNRTIs; FDA Approval May Be Drawing Near: A Blog Entry by Myles Helfand (July 28, 2010)
In The XVIII International AIDS Conference, from TheBodyPRO.com
- TMC278 Noninferior to Efavirenz in Naive But With More Virologic Failures (July 22, 2010)
From National AIDS Treatment Advocacy Project
- Peering in the Pipeline (Summer 2009)
To read PDF, click here.
In Achieve, from ACRIA and GMHC
- Drug Watch: Nanotechnology for Antiretroviral Delivery (Winter/Spring 2009)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Once-a-Month HIV Therapy: Could Nanotechnology Be the Next Treatment Frontier? (April 2008)
A simple explanation of new research on the use of nanotechnology in HIV treatment.
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Drug Watch: Next-Generation NNRTIs: Etravirine and Rilpivirine (Winter 2008)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- An Alternative NNRTI, TMC278, Progresses in Development (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- NNRTIs: The Next Generation Approaches (Part I) (December 14, 2006)
From TheBodyPRO.com
- New Drugs From Old Classes (Spring 2006)
A listing of NNRTIs, NRTIs and protease inhibitors currently in development.
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America
- NNRTIs in Development (March 30, 2006)
An overview from Edwin DeJesus, M.D.
From TheBody.com
|
Advertisement
|
Email
Glossary
